ArticleScience advances2026
Palladium-catalyzed enantioselective alkenylation of acyclic alkenols: Broad scope with alkenyl bromides.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palladium-catalyzed enantioselective Heck alkenylation of acyclic alkenols offers a promising strategy for constructing highly valuable stereodefined alkenylated carbonyl compounds from simple precursors. However, precise control of site-selective β-hydride elimination in this transformation remains an unresolved challenge. We have developed a highly enantioselective intermolecular Heck reaction to encompass various alkenyl bromides and acyclic primary or racemic secondary alkenols. The success of this reaction is attributed to the use of chiral BINOL ligands substituted with halogens at the 3,3'-positions, which offer selective β-hydride elimination followed by migration of the catalyst along the alkyl chain to provide the alkenylated carbonyl products. Successive applications enable alkenylation of trisubstituted alkenols and stereodivergent access to four stereoisomers with excellent enantio- and diastereoselectivity. Mechanistic studies indicated that 3,3'-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.